Biological Agent Therapy for IgA Vasculitis(HSP)
Abstract
pain, and kidney involvement, among which kidney involvement (IgAVN) is a serious complication. 1% to 5% of patients may progress to
end-stage renal disease. Traditional glucocorticoids and immunosuppressants have limitations in efficacy and adverse reactions, and biologics
offer a new direction for its treatment. This article systematically explores the therapeutic effects and mechanisms of rituximab, ofatumumab,
natalizumab, and telitacicept on IgAV (especially IgAVN), and investigates their clinical value, with the aim of providing new evidence for the
treatment of IgAV (including refractory cases).
Keywords
Full Text:
PDFReferences
[1] Li Y, Zhou Y, Zhu D, Wang Y. The role of T cells in the development of Henoch-Schonlein purpura. Front Biosci (Landmark Ed). 2018.
23(5): 837-851.
[2] Pillebout E, Sunderktter C. IgA vasculitis. Semin Immunopathol. 2021;43(5):72938.
[3] Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nat Rev Rheumatol. 2022;18(1):2234.
[4] Shim JO, Han K, Park S, Kim GH, Ko JS, Chung JY. Ten-year Nationwide Population-based Survey on the Characteristics of Children
with Henoch-Sch?nlein Purpura in Korea. J Korean Med Sci. 2018. 33(25): e174.
[5] Micheletti RG, Werth VP. Small vessel vasculitis of the skin. Rheum Dis Clin North Am. 2015. 41(1): 21-32, vii.
[6] Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schnlein purpura, Kawasaki disease, and rare
vasculitides in children of different ethnic origins. Lancet. 2002. 360(9341): 1197-202.
[7] Nielsen HE. Epidemiology of Schnlein-Henoch purpura. Acta Paediatr Scand. 1988. 77(1): 125-31.
[8] Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch-Schnlein purpura in an unselected childhood population. Eur J Pediatr. 1988. 147(2): 113-5.
[9] Yoshikawa N, Ito H, Yoshiya K, et al. Henoch-Schoenlein nephritis and IgA nephropathy in children: a comparison of clinical course.
Clin Nephrol. 1987. 27(5): 233-7.
[10] Counahan R, Winterborn MH, White RH, et al. Prognosis of Henoch-Schnlein nephritis in children. Br Med J. 1977. 2(6078): 11-4.
[11] Bunchman TE, Mauer SM, Sibley RK, Vernier RL. Anaphylactoid purpura: characteristics of 16 patients who progressed to renal failure. Pediatr Nephrol. 1988. 2(4): 393-7.
[12] Saulsbury FT. Epidemiology of Henoch-Schnlein purpura. Cleve Clin J Med. 2002. 69 Suppl 2: SII87-9.
[13] Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016. 2: 16001.
[14] Willey CJ, Coppo R, Schaefer F, Mizerska-Wasiak M, Mathur M, Schultz MJ. The incidence and prevalence of IgA nephropathy in Europe. Nephrol Dial Transplant. 2023. 38(10): 2340-2349.
[15] Batu ED, Sener S, Ozen S. COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis.
Semin Arthritis Rheum. 2022. 55: 152047.
[16] Miller WR, Buelow JM, Bakas T. Older adults and new-onset epilepsy: experiences with diagnosis. J Neurosci Nurs. 2014. 46(1): 2-10.
[17] Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and
a review of the literature. Pediatr Rheumatol Online J. 2018. 16(1): 71.
[18] Hackl A, Becker JU, Krner LM, et al. Mycophenolate mofetil following glucocorticoid treatment in Henoch-Schnlein purpura nephritis: the role of early initiation and therapeutic drug monitoring. Pediatr Nephrol. 2018. 33(4): 619-629.
[19] Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable
target?[J]. Autoimmun Rev, 2013, 12(8): 835-838.
[20] Xiong Y, Cuevas S, Xu G, Zou H. The efficacy of rituximab in the treatment of IgA vasculitis nephritis. Clin Exp Med. 2024 Sep
9;24(1):213.
[21] Hernndez-Rodrguez J, Carbonell C, Mirn-Canelo JA, Diez-Ruiz S, Marcos M, Chamorro AJ. Rituximab treatment for IgA vasculitis:
A systematic review. Autoimmun Rev. 2020 Apr;19(4):102490.
[22] Maritati, F.; Fenoglio, R.; Pillebout, E.; Emmi, G.; Urban, M.L.; Rocco, R.; Nicastro, M.; Incerti, M.; Goldoni, M.; Trivioli, G.; et al. Brief
[23] Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Sch nlein). Arthritis Rheumatol. 2018, 70, 109 114.
[24] Fenoglio, R.; Sciascia, S.; Naretto, C.; De Simone, E.; Del Vecchio, G.; Ferro, M.; Quattrocchio, G.; Roccatello, D. Rituximab in severe
immunoglobulin-A vasculitis (Henoch-Sch nlein) with aggressive nephritis. Clin. Exp. Rheumatol. 2020, 38 (Suppl. S124), 195 200.
[25] Lundberg S, Westergren E, Smolander J, Bruchfeld A. B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017 Feb;10(1):20-26
[26] Reynolds BC, Lamb A, Jones CA, Yadav P, Tyerman KS, Geddes CC (2022) UK experience of ofatumumab in recur-rence of focal segmental glomerulosclerosis post-kidney trans-plant. Pediatr Nephrol 37(1):199 207.
[27] Haarhaus ML, Svenungsson E, Gunnarsson I (2016) Ofatumumab treatment in lupus nephritis patients. Clin Kidney J 9(4):552 555.
Glumova A, Karp A et al (2017) Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol 32(5):835 841.
[28] Ravani P, Pisani I, Bodria M, Caridi G, Degl' Innocenti ML, Ghiggeri GM (2020) Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol 35(6):997 1003.
[29] Selvaskandan H, Kay Cheung C, Dormer J, Wimbury D, Mar-tinez M, Xu G et al (2020) Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis. Nephron 144(9):453 458
[30] Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671-5
[31] Li SX, Hu RK, Kong DL, Xu J, Bian Q, Guo ZY, Mei XB. Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report.
Front Immunol. 2025 May 1;16:1564242.
[32] Jin Y, Sheng A, Lin Q, He X, Fu H, Mao J. Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept. CEN Case Rep. 2025 Jun;14(3):402-407.
DOI: http://dx.doi.org/10.70711/mhr.v2i8.8023
Refbacks
- There are currently no refbacks.
